<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02607280</url>
  </required_header>
  <id_info>
    <org_study_id>DS5565-A-J313</org_study_id>
    <nct_id>NCT02607280</nct_id>
  </id_info>
  <brief_title>DS-5565 Phase III Study for Renal Impairment in Japanese Subjects</brief_title>
  <official_title>A JAPANESE, PHASE 3, OPEN-LABEL, 14-WEEK STUDY OF DS-5565 IN PATIENTS WITH PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY WITH RENAL IMPAIRMENT OR POST-HERPETIC NEURALGIA WITH RENAL IMPAIRMENT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CMIC Co, Ltd. Japan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigate the safety and efficacy of DS-5565 in Japanese subjects with Diabetic Peripheral
      Neuropathic Pain (DPNP) with renal impairment or Post-Herpetic Neuralgia (PHN) with renal
      impairment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective is the safety and tolerability of DS-5565 in Japanese subjects with
      moderate to severe renal impairment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2015</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number and severity of adverse events</measure>
    <time_frame>14 weeks</time_frame>
    <description>the number of treatment emergent adverse events and the severity of them</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Diabetic Peripheral Neuropathic Pain</condition>
  <condition>Post-herpetic Neuralgia</condition>
  <arm_group>
    <arm_group_label>DS-5565 group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DS-5565 15 mg (for moderate renal impairment) or 7,5 mg (for severe renal impairment), oral administration, Treatment period; 2-weeks titration and 12-weeks fixed dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DS-5565</intervention_name>
    <description>DS-5565 15 mg (for moderate renal impairment) or 7,5 mg (for severe renal impairment), oral administration, Treatment period; 2-weeks titration and 12-weeks fixed dose</description>
    <arm_group_label>DS-5565 group</arm_group_label>
    <other_name>mirogabalin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At screening, creatinine clearance (using the Cockcroft-Gault equation): 15-59 mL/min

          -  At screening, a pain scale of â‰¥ 40 mm

          -  Type 1 or type 2 diabetes mellitus at screening (for patients with diabetic peripheral
             neuropathic pain DPNP only)-. Painful distal symmetric polyneuropathy (for patients
             with DPNP only)

          -  post-herpetic neuralgia PHN defined as pain present for more than 3 months after
             herpes zoster skin rash at screening (for patients with PHN only)

        Exclusion Criteria:

          -  HbA1c (National Glycohemoglobin Standardization Program) &gt; 10.0% (for patients with
             DPNP only)

          -  Previous use of neurolytic block (for patients with PHN only)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Shonan Kamakura General Hospital</name>
      <address>
        <city>Kamakura-shi</city>
        <state>Kanagawa</state>
        <zip>247-8533</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 16, 2015</study_first_submitted>
  <study_first_submitted_qc>November 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2015</study_first_posted>
  <last_update_submitted>April 17, 2017</last_update_submitted>
  <last_update_submitted_qc>April 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetic peripheral neuropathic pain</keyword>
  <keyword>post-herpetic neuralgia</keyword>
  <keyword>renal impairment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Neuralgia, Postherpetic</mesh_term>
    <mesh_term>Diabetic Neuropathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

